Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effects of Intranasal Insulin on Neuroimaging Markers and Cognition in Patients With Psychotic Disorders

NCT03943537 is registered in ClinicalTrials.gov with Mclean Hospital as lead sponsor.

NCT NCT03943537
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03943537 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effects of Intranasal Insulin on Neuroimaging Markers and Cognition in Patients With Psychotic Disorders
Lead sponsor
Mclean Hospital
Phase
Phase 2
Overall status
Completed
Start date
October 1, 2019
Completion date
February 23, 2024
Enrollment
87 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

bipolar i disorder, psychosis, schizo affective disorder, schizophrenia